Natural convection within water-zno nanofluid-filled hemispherical enclosure with a cubic electronic device

This work qualifies and quantifies the nanofluidic natural convective phenomena occurring in a hemispherical enclosure used for electronics applications. This cavity consists of a disk thermally insulated on its rear face, an active cube centered on the disk which generates a constant heat flux and an isothermal dome. The disc of the cavity remains horizontal while its dome is oriented either upwards or downwards. The considered nanofluid is a mixture of water with metallic ZnO nanoparticles. In order to examine the influence of these nanoparticles on the natural convective heat transfer, three values of the volume fraction considered: 0% (pure water), 1% and 5%. The dimensionless governing system of the problem under consideration is solved by means of the control volume method in combination with the SIMPLE algorithm. The structured mesh is composed of triangular surfacic elements and tetrahedral in the volumic domain. Temperature and velocity distributions are presented for some configurations and convective heat transfer is examined for all processed ones. The natural convective heat transfer is quantified by means of Nusselt-Rayleigh-Prandtl correlations.Papers presented at the 13th International Conference on Heat Transfer, Fluid Mechanics and Thermodynamics, Portoroz, Slovenia on 17-19 July 2017 .International centre for heat and mass transfer.American society of thermal and fluids engineers

Aerodynamics in the open channel of the Sistan-type wind-mill with vertical axis wind turbine

International Journal of Numerical Methods for Heat and Fluid FlowThe purpose of this paper is to examine the details of the air mass flow and aerodynamical phenoména across a channel containing a large vertical axis wind turbine. The considered model reproduces as closely as possible the real assembly of the Sistan-type wind-mill whose top is open. The technical results of this work could be used for the restoration and operation of this assembly whose historical and architectural values are recognized.L'objectif de cet article est d’examiner les détails d'un écoulement dans un canal contenant une turbine à axe vertical. Les résultats techniques de ce travail pourront être utilisés pour la restauration et la mise en service de ce dispositif dont la valeur historique et architecturale est reconnue

Strategies and Programs for Improved Nutrient Use Efficiency, Doubling Farmer’s Income, and Sustainable Agriculture: Indian Context

Since the Green Revolution era, the farming sector exploited the soils for food, fiber, fodder, etc., with high input responsive varieties that excavated vast amounts of chemical fertilizers. The burgeoning population of the country calls for a commensurate increase in food production to satisfy the demands of its inhabitants. Further, due to innovative mechanization in agriculture, specialization, and government policy programs, the productivity of food has soared. Subsequently, it ensued greater productions and minimized food prizes. Regrettably, intensive agricultural operations degraded the soil quality and now reached such a stage where without external inputs, growers unable to achieve their targeted yields. India has lost 68% innate productive capacity of agricultural soils. This plunder of land’s quality continues unabated, further resulting in low nutrient use efficiency and insufficient yields of agroecosystems. Therefore, this is high time to realize the dreadful impacts of intensive crop production on the natural ecosystem. Irrefutably, both soil and its nutrients are the wondrous gifts of nature to humankind; utilizing them sustainably is imperative. The present chapter highlights the impacts of non-judicious nutrient management on soil productivity, nutrient use efficiency, and novel technologies required to promote sustainable agriculture and achieve the target of doubling farmer’s income in India

The tale of TILs in breast cancer : a report from The International Immuno-Oncology Biomarker Working Group

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC

Natural products in drug discovery: advances and opportunities

Natural products and their structural analogues have historically made a major contribution to pharmacotherapy, especially for cancer and infectious diseases. Nevertheless, natural products also present challenges for drug discovery, such as technical barriers to screening, isolation, characterization and optimization, which contributed to a decline in their pursuit by the pharmaceutical industry from the 1990s onwards. In recent years, several technological and scientific developments — including improved analytical tools, genome mining and engineering strategies, and microbial culturing advances — are addressing such challenges and opening up new opportunities. Consequently, interest in natural products as drug leads is being revitalized, particularly for tackling antimicrobial resistance. Here, we summarize recent technological developments that are enabling natural product-based drug discovery, highlight selected applications and discuss key opportunities

The path to a better biomarker: Application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice

Immune checkpoint inhibitor therapies targeting PD-1/PD-L1 are now the standard of care in oncology across several hematologic and solid tumor types, including triple negative breast cancer (TNBC). Patients with metastatic or locally advanced TNBC with PD-L1 expression on immune cells occupying 651% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab-paclitaxel. However, concerns regarding variability between immunohistochemical PD-L1 assay performance and inter-reader reproducibility have been raised. High tumor-infiltrating lymphocytes (TILs) have also been associated with response to PD-1/PD-L1 inhibitors in patients with breast cancer (BC). TILs can be easily assessed on hematoxylin and eosin\u2013stained slides and have shown reliable inter-reader reproducibility. As an established prognostic factor in early stage TNBC, TILs are soon anticipated to be reported in daily practice in many pathology laboratories worldwide. Because TILs and PD-L1 are parts of an immunological spectrum in BC, we propose the systematic implementation of combined PD-L1 and TIL analyses as a more comprehensive immuno-oncological biomarker for patient selection for PD-1/PD-L1 inhibition-based therapy in patients with BC. Although practical and regulatory considerations differ by jurisdiction, the pathology community has the responsibility to patients to implement assays that lead to optimal patient selection. We propose herewith a risk-management framework that may help mitigate the risks of suboptimal patient selection for immuno-therapeutic approaches in clinical trials and daily practice based on combined TILs/PD-L1 assessment in BC. \ua9 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic triple-negative breast cancer (TNBC). To incorporate sTILs into clinical trials and diagnostics, reliable assessment is essential. In this review, we propose a new concept, namely the implementation of a risk-management framework that enables the use of sTILs as a stratification factor in clinical trials. We present the design of a biomarker risk-mitigation workflow that can be applied to any biomarker incorporation in clinical trials. We demonstrate the implementation of this concept using sTILs as an integral biomarker in a single-center phase II immunotherapy trial for metastatic TNBC (TONIC trial, NCT02499367), using this workflow to mitigate risks of suboptimal inclusion of sTILs in this specific trial. In this review, we demonstrate that a web-based scoring platform can mitigate potential risk factors when including sTILs in clinical trials, and we argue that this framework can be applied for any future biomarker-driven clinical trial setting